NTU Singapore partners with SUSTech and Lipigon Pharmaceuticals to develop an inhaled RNA therapy that reduces excessive lung inflammation after severe infections.
← News
Tech for Good Tech for Good Frontiers
Inhaled RNA therapy cuts lung inflammation after severe infections in preclinical tests
Preclinical Tests Research stage
Inhaled RNA Therapy Treatment type
Post-Infection Inflammation Target
3 Institutions Partners